Cargando…

Developing a new score system for patients with PSA ranging from 4 to 20 ng/mL to improve the accuracy of PCa detection

OBJECTIVE: To develop a new score system for patients with prostate specific antigen (PSA) ranging from 4 to 20 ng/mL to improve the accuracy of prostate cancer (PCa) detection, and to evaluate it with receiver operating characteristic curve. METHODS: A total of 797 patients (208 with prostate cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Yuxiao, Huang, Yuan, Cheng, Gong, Zhang, Cheng, Wu, Jie, Qin, Chao, Hua, Lixin, Wang, Zengjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011463/ https://www.ncbi.nlm.nih.gov/pubmed/27652058 http://dx.doi.org/10.1186/s40064-016-3176-3

Ejemplares similares

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?
por: Lee, Seung Hwan, et al.
Publicado: (2011)

Developing a Follow-Up Strategy for Patients with PSA Ranging from 4 to 10 ng/ml via a New Model to Reduce Unnecessary Prostate Biopsies
por: Zhao, Ruizhe, et al.
Publicado: (2014)

Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA >20 ng/mL
por: Hinev, Alexander I., et al.
Publicado: (2012)

Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range
por: Vukovic, I., et al.
Publicado: (2017)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL
por: Wang, Zhi-bing, et al.
Publicado: (2021)

Comparison of (68)Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4–20 ng/ml before the initial biopsy
por: Li, Yu, et al.
Publicado: (2020)

Development and validation of a nomogram for predicting prostate cancer in patients with PSA ≤ 20 ng/mL at initial biopsy
por: Wu, Qiang, et al.
Publicado: (2021)

The likelihood of having serum level of PSA of ≥4.0 ng/mL and ≥10.0 ng/mL in non-obese and obese Nigerian men with LUTS
por: Adegun, Patrick Temi, et al.
Publicado: (2015)

The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
por: Shaida, Nadeem, et al.
Publicado: (2009)

Evaluation of PCA3 and multiparametric MRI’s: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL
por: Okcelik, Sezgin, et al.
Publicado: (2016)

Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4–20 ng/mL
por: Zheng, Yuxin, et al.
Publicado: (2022)

PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5–10.0 ng ml(-1) and 10.1–20.0 ng ml(-1): a multicenter study
por: Lin, Yu-Rong, et al.
Publicado: (2015)

Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL
por: Zhou, Yongqiang, et al.
Publicado: (2017)

A pilot study on the use of serum glyoxalase as a supplemental biomarker to predict malignant cases of the prostate in the PSA range of 4-20 ng/ml
por: Chavan, Sushant V., et al.
Publicado: (2011)

Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml
por: Ferro, Matteo, et al.
Publicado: (2013)

Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml
por: Kumar, Niraj, et al.
Publicado: (2019)

AB013. The study on the diagnostic value of f/tPSA to the prostate cancer with tPSA greater than 10 ng/mL
por: Li, Yan-Feng, et al.
Publicado: (2016)

Active surveillance in intermediate-risk prostate cancer with PSA 10–20 ng/mL: pathological outcome analysis of a population-level database
por: Lonergan, Peter E., et al.
Publicado: (2021)

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL
por: Iwamoto, Hiroaki, et al.
Publicado: (2019)

Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?
por: Busato, W. F. S., et al.
Publicado: (2015)

Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL
por: Gomez Gomez, Enrique, et al.
Publicado: (2019)

Impact of Comorbidity, Race, and Marital Status in Men Referred for Prostate Biopsy with PSA >20 ng/mL: A Pilot Study in High-Risk Patients
por: Klaassen, Zachary, et al.
Publicado: (2014)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Stromal Tumor of Uncertain Malignant Potential (STUMP) With PSA >500 ng/ml: A Case Report
por: Johnson, Michael H., et al.
Publicado: (2015)

Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA
por: Zhao, Jing, et al.
Publicado: (2016)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

Correction: Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL
Publicado: (2020)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml(–1)
por: Wang, Cheng, et al.
Publicado: (2021)

Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4∼10 ng/mL
por: Lu, Yangbai, et al.
Publicado: (2022)

Correlation of Serum Androgens and Pituitary Hormone Levels with Serum PSA Less Than 2.5 NG/ML
por: Sofikerim, Mustafa, et al.
Publicado: (2007)

Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China
por: Dai, Zhihong, et al.
Publicado: (2021)

Clinical utility of serum folate measurement in tertiary care patients: Argument for revising reference range for serum folate from 3.0 ng/mL to 13.0 ng/mL
por: Singh, Gurmukh, et al.
Publicado: (2015)

Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score
por: Fang, Dong, et al.
Publicado: (2015)

Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL
por: Tutrone, Ronald, et al.
Publicado: (2020)

Comparison of Multiparametric and Biparametric MRI in First Round Cognitive Targeted Prostate Biopsy in Patients with PSA Levels under 10 ng/mL
por: Lee, Dong Hoon, et al.
Publicado: (2017)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0–10.0 ng/mL) in Nigeria
por: Ezenwa, E.V., et al.
Publicado: (2012)

Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with PSA levels between 2.6 and 10.0 ng/mL
por: Castro, Hugo A. Socrates, et al.
Publicado: (2018)

Explication of the roles of prostate health index (PHI) and urokinase plasminogen activator (uPA) as diagnostic and predictor tools for prostate cancer in equivocal PSA range of 4–10 ng/mL
por: Nassir, Anmar M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2lkg4s2p04rfrlii6p28tmgh39